drugset / Trial / NCT03774537

Human Mesenchymal Stem Cells For Infants At High Risk For Bronchopulmonary Dysplasia

NCT03774537

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is an open-label, single-center, dose escalation study to evaluate of safety and efficacy of human umbilical cord -derived mesenchymal stem cells (hUC-MSCs) in premature infants at high risk for Bronchopulmonary Dysplasia(BPD)

Timeline

Start
2019-03-01
Primary completion
2020-12-01
Completion
2021-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject human umbilical cord mesenchymal stem cells Cell therapy 1 cells/kg Intravenous
Subject human umbilical cord mesenchymal stem cells Cell therapy 5 cells/kg Intravenous